BBTX
Bambusa Therapeutics, Inc. (BBTX)
Healthcare • NASDAQ • $15.98-0.68%
- Symbol
- BBTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $15.98
- Daily Change
- -0.68%
- Market Cap
- $819.66M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $17.65
- 52W Low
- $13.60
- Analyst Target
- N/A
- Dividend Yield
- 0.00%
- Beta
- N/A
Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The company also develops BBT004 for depletion of pathogenic B cells and antibody-producing plasma cells in autoantibody-driven autoimmune diseases. The company operates in the United St…
Company websiteResearch BBTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.